Luc Truyen, MD, PhD

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed what makes ponesimod different from other currently FDA-approved treatments.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed the results of a phase 2 core and extension study of ponesimod in patients with relapsing-remitting multiple sclerosis.